ANI Pharma (ANIP) Tops Q3 EPS by 11c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to ANI Pharma (ANIP) Tops Q3 EPS by 11c, Offers Guidance

ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues

November 9, 2022 6:50 AM EST

Third Quarter 2022 Results:

-- Net revenues of $83.8 million, net loss available to common shareholders of $(9.0) million and diluted GAAP loss per share of $(0.55) --

-- Adjusted non-GAAP EBITDA of $19.6 million and adjusted non-GAAP diluted earnings per share of $0.64 --

-- Year-over-year net revenue growth of 61% resulting in record quarterly net revenues --

-- Lead Rare Disease asset, Purified Cortrophin® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin) net sales of $12.6 million --

Full-Year 2022... More